Angiogenèse
Les inhibiteurs de l'angiogenèse sont des composés qui interfèrent avec la formation de nouveaux vaisseaux sanguins, un processus crucial dans la croissance et la métastase des cancers. En inhibant l'angiogenèse, ces composés peuvent restreindre l'apport sanguin aux tumeurs, ralentissant ou arrêtant leur croissance. Les inhibiteurs de l'angiogenèse sont essentiels dans la recherche sur le cancer et le développement thérapeutique, offrant des informations sur les mécanismes de progression tumorale et proposant des traitements potentiels pour le cancer et d'autres maladies liées à l'angiogenèse. Chez CymitQuimica, nous offrons une large gamme d'inhibiteurs de l'angiogenèse de haute qualité pour soutenir vos recherches en oncologie et biologie vasculaire.
Sous-catégories appartenant à la catégorie "Angiogenèse"
- BTK(145 produits)
- Bcr-Abl(102 produits)
- EGFR(572 produits)
- FAK(72 produits)
- FLT(92 produits)
- Récepteur du facteur de croissance des fibroblastes (FGFR)(170 produits)
- JAK(245 produits)
- PDGFR(126 produits)
- RAAS(86 produits)
- Src(78 produits)
- Syk(38 produits)
- Thrombine(47 produits)
- VDA(2 produits)
- VEGFR(268 produits)
Affichez 6 plus de sous-catégories
1414 produits trouvés pour "Angiogenèse"
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
EGFR-IN-87
CAS :<p>EGFR-IN-87 is an EGFR tyrosine kinase inhibitor with potent inhibitory activity, exhibiting IC50 values of 3.1 nM, 1.3 nM, and 7.1 nM against EGFR_d746-750,</p>Formule :C28H33N7O2Degré de pureté :98.64%Couleur et forme :SolidMasse moléculaire :499.61KER047
CAS :<p>ALK2-IN-4, a highly effective ALK2 inhibitor.</p>Formule :C26H30FN7ODegré de pureté :98.49% - >99.99%Couleur et forme :SolidMasse moléculaire :475.56IN-1130
CAS :<p>IN-1130: ALK5 inhibitor, IC50 - 5.3 nM (Smad3), 36 nM (casein), 4.3 μM (p38α MAPK).</p>Formule :C25H20N6ODegré de pureté :99.79%Couleur et forme :SolidMasse moléculaire :420.47HM43239
CAS :<p>HM43239: oral FLT3 inhibitor; IC50: FLT3 WT 1.1nM, ITD 1.8nM, D835Y 1.0nM; blocks p-STAT5/p-ERK; affects SYK, JAK1/2, TAK1; halts leukemia cell growth.</p>Formule :C29H33ClN6Degré de pureté :99.7%Couleur et forme :SolidMasse moléculaire :501.07HER2-IN-21
CAS :<p>HER2-IN-21 (compound 657994) is an inhibitor of the human epidermal growth factor receptor 2 (HER2) with an IC50 value of 3.85 μM.</p>Formule :C20H18N4O3SCouleur et forme :SolidMasse moléculaire :394.447VEGFR/PDGFR-IN-1
CAS :<p>VEGFR/PDGFR-IN-1 (Compound 1) is an inhibitor of VEGFR with an IC50 of 0.4 μM. It can inhibit angiogenesis in HUVEC cells and holds promise for impeding tumor growth and metastasis.</p>Formule :C17H21N5O3Couleur et forme :SolidMasse moléculaire :343.38TZEP7
CAS :<p>TZEP7 functions as an EGFR kinase inhibitor in cancer cells. It exhibits cytotoxicity and induces apoptosis within these cells. TZEP7 downregulates the anti-apoptotic protein Bcl-2, upregulates the pro-apoptotic protein Bax, and increases caspase levels. This compound holds potential for research in anticancer drug development.</p>Formule :C27H19ClFNSCouleur et forme :SolidMasse moléculaire :443.963FGFR1 inhibitor-17
CAS :<p>FGFR1inhibitor-17 (Compound 92) is a potent inhibitor of FGFR1, with promising applications in cancer research.</p>Formule :C16H13ClN2O3Couleur et forme :SolidMasse moléculaire :316.739TrxR/EGFR-IN-1
CAS :<p>TrxR/EGFR-IN-1 (Compound L1Au2) is a TrxR/EGFR inhibitor with activity against both gefitinib-sensitive and -resistant lung cancer, effectively suppressing tumor proliferation and promoting apoptosis. It enhances GPX4 degradation through autophagosome-lysosome and proteasome pathways, leading to ferroptosis. Additionally, it induces endoplasmic reticulum stress and triggers immunogenic cell death, making it applicable for studies on gefitinib-resistant lung cancer.</p>Formule :C24H24AuClFN6O2PCouleur et forme :SolidMasse moléculaire :710.878Tyrosine kinase-IN-9
CAS :<p>Tyrosine kinase-IN-9 (Compound B) is an inhibitor of c-Abl. It is useful for studying neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.</p>Formule :C20H14ClN3O3Couleur et forme :SolidMasse moléculaire :379.796TGF-βRI inhibitor 3
CAS :<p>TGF-βRI inhibitor 3 (Compound 9ac) is a selective inhibitor of TGF-β that effectively suppresses the TGF-β signaling pathway. It exhibits IC50 values of 13 μM for c-Src kinase and 0.63 μM for ALK5 kinase.</p>Formule :C21H21NO4Couleur et forme :SolidMasse moléculaire :351.396lirucitinib
CAS :<p>Lirucitinib is a JAK inhibitor known for its anti-inflammatory properties.</p>Formule :C16H25N5OSCouleur et forme :SolidMasse moléculaire :335.468LNK01004
CAS :<p>LNK01004 is a JAK inhibitor that exhibits potent inhibitory effects on JAK1 (IC50: 10 nM), JAK2 (IC50: ＜0.51 nM), and TYK2 (IC50: 1.0 nM). It can concurrently inhibit multiple cytokine-induced p-STAT signaling pathways and is applicable for research on diseases such as atopic dermatitis.</p>Formule :C26H31N7O2Couleur et forme :SolidMasse moléculaire :473.57EGFR-IN-147
CAS :<p>EGFR-IN-147 (compound ID-5841161) is a potent EGFR inhibitor, demonstrating a 14% inhibition rate at a concentration of 1μM. It holds promise for cancer research applications.</p>Formule :C13H13N5OCouleur et forme :SolidMasse moléculaire :255.275VEGFR-2-IN-65
CAS :<p>VEGFR-2-IN-65 (Compound 07) functions as a VEGFR-2 inhibitor. It forms hydrogen bonds with Cys180 and can inhibit tube formation in HUVECs.</p>Formule :C21H18N2O3Couleur et forme :SolidMasse moléculaire :346.379Milpecitinib
CAS :<p>Milpecitinib (Compound 21a) is a potent and selective Janus tyrosine kinase (JAK) inhibitor with anti-inflammatory properties. It shows promise for research in cancer and inflammatory diseases.</p>Formule :C20H20N4O2SCouleur et forme :SolidMasse moléculaire :380.463DA-0157
CAS :<p>DA-0157 is an orally active inhibitor targeting EGFR and ALK, designed to overcome resistance mutations in non-small cell lung cancer (NSCLC). It effectively inhibits the proliferation of Ba/F3-EGFR Del19/T790M/C797S (IC50= 6.9 nM), Ba/F3-EGFR WT (IC50= 0.83 μM), Ba/F3-EML4-ALK-L1196M (IC50= 5.5 nM), and Ba/F3-EML4-ALK (IC50= 7.4 nM). Additionally, DA-0157 inhibits CYP2D6 with an IC50 of 5.26 μM and demonstrates antitumor activity in mouse models.</p>Formule :C31H43BrN7O2PCouleur et forme :SolidMasse moléculaire :656.597FGFR1 inhibitor-16
CAS :<p>FGFR1inhibitor-16 (Compound 89) functions as an FGFR1 inhibitor, demonstrating an inhibition rate of 53.00% at a concentration of 50 μM and 24.95% at 10 μM. It is utilized in tumor research.</p>Formule :C16H9N5O3SCouleur et forme :SolidMasse moléculaire :351.339FAK-IN-3
<p>FAK-IN-3 inhibits FAK, reduces PA-1 cell migration/invasion, and tumor growth, with no major side effects.</p>Formule :C28H28N6O4Couleur et forme :SolidMasse moléculaire :512.56FGFR4-IN-7
<p>FGFR4-IN-7 is a covalent, reversible FGFR4 inhibitor (IC50: 0.42 μM) that blocks the FGFR4 signaling pathway, thereby inducing apoptosis.</p>Formule :C26H25Cl2N5O3Couleur et forme :SolidMasse moléculaire :526.41VEGFR-2-IN-13
<p>VEGFR-2-IN-13 (Compound 19a) is a potent VEGFR-2 inhibitor (IC50: 3.4 nM). vEGFR-2-IN-13 arrests the HepG2 cell cycle in G2/M phase and induces apoptosis.</p>Formule :C24H18N6O2SCouleur et forme :SolidMasse moléculaire :454.5EGFR-IN-44
<p>EGFR-IN-44: potent EGFR kinase inhibitor, orally active, IC50 4.11 nM, 33.57% bioavailability, induces apoptosis, for lung cancer study.</p>Formule :C27H29ClN6O2SCouleur et forme :SolidMasse moléculaire :537.08DBMB
CAS :<p>DBMB is a spleen tyrosine kinase (Syk) inhibitor that significantly suppresses Syk enzyme activity. It possesses anti-inflammatory properties by inhibiting NF-κB signaling, thereby reducing the production of inflammatory mediators such as nitric oxide (NO) and prostaglandin E2 (PGE2). DBMB can be utilized in research on inflammatory diseases.</p>Formule :C24H22N4OCouleur et forme :SolidMasse moléculaire :382.458BTK-IN-8
<p>BTK-IN-8: potent, selective covalent BTK inhibitor; IC50=0.22 nM, Kd=0.91 nM; effective in blood CD69 cells (IC50=0.029 μM).</p>Formule :C26H36N6O3Couleur et forme :SolidMasse moléculaire :480.6FAK-IN-23
CAS :<p>FAK-IN-23 (Compound II) is an inhibitor of focal adhesion kinase (FAK).</p>Formule :C32H38F3N5O8Couleur et forme :SolidMasse moléculaire :677.668HSN748
CAS :<p>HSN748 is an analog of ponatinib and acts as a multi-kinase inhibitor. It exhibits inhibitory activity against kinases such as FLT3, ABL1, RET, PDGFRα/β, MNK1, and MNK2. HSN748 can suppress the growth of chronic myeloid leukemia and acute myeloid leukemia cell lines, making it a useful compound in leukemia research.</p>Formule :C27H24F3N7OCouleur et forme :SolidMasse moléculaire :519.521JBJ-02-112-05
CAS :<p>JBJ-02-112-05 is a potent, mutant-selective, allosteric and orally active inhibitor of EGFR with an IC 50 of 15 nM for EGFR L858R/T790M [1].</p>Formule :C27H20N4O2SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :464.54EGFR-IN-38
CAS :<p>EGFR-IN-38: low-toxic acrylamide-derived EGFR inhibitor, targets NSCLC, patented for research on EGFR mutation-related diseases.</p>Formule :C25H24ClN7O2Couleur et forme :SolidMasse moléculaire :489.96Flonoltinib sulfate
CAS :<p>Flonoltinib maleate is an orally active dual inhibitor of JAK2/FLT3, with IC50 values of 0.7 nM for JAK2, 4 nM for FLT3, 26 nM for JAK1, and 39 nM for JAK3. It exhibits anticancer properties.</p>Formule :C25H36FN7O5SCouleur et forme :SolidMasse moléculaire :565.661TX2-121-1
CAS :<p>TX2-121-1 targets HER3 for proteasome-mediated degradation to inhibit HER3-dependent signalling and growth.</p>Formule :C42H52N8O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :716.91CEP-14083
CAS :<p>CEP-14083: potent ALK inhibitor, effective in NPM/ALK T-cell lymphoma, binds ATP site; IC50=11 nmol/L, also inhibits insulin receptor, preclinical efficacy.</p>Formule :C31H30N6O2Couleur et forme :SolidMasse moléculaire :518.61E6201
CAS :<p>E6201, a dual kinase inhibitor, blocks MEK1/FLT3 and has anti-tumor/psoriasis effects with low IC50s: ERK2 (5.2 nM), JNK (91 nM), p38 MAPK (19 nM).</p>Formule :C21H27NO6Couleur et forme :SolidMasse moléculaire :389.44SJ-C1044
CAS :<p>SJ-C1044 is an orally effective pan-RAF inhibitor demonstrating immunomodulatory and antitumor activities. It targets wild-type BRAF, wild-type CRAF, and BRAF(V600E) with IC50 values of 331, 257, and 187 nM, respectively. SJ-C1044 suppresses tumor cell proliferation by inhibiting kras activation and MEK-ERK phosphorylation. Additionally, it shows inhibition of VEGFR2, TIE2, and CSF1R, with IC50 values of 100, 23, and 235 nM respectively. The compound enhances the tumor immune microenvironment through inhibition of angiogenesis and modulation of macrophage function. SJ-C1044 is applicable for research in colorectal cancer.</p>Formule :C25H14F7N7OCouleur et forme :SolidMasse moléculaire :561.41Paeoniflorin-6′-O-benzene sulfonate
CAS :<p>Paeoniflorin-6′-O-benzene sulfonate (CP-25) acts as an inhibitor of G protein-coupled receptor kinase 2 (GRK2), preventing its translocation to the cell membrane and inhibiting the JAK1/STAT3 signaling pathway. It suppresses HaCaT cell proliferation induced by IL-17A/CXCL2. In mouse models, CP-25 reduces the levels of inflammatory cytokines and chemokines such as IL-17A, IL-17F, IFN-γ, TNF-α, IL-22, IL-23, CXCL2, CXCL3, and CXCL9, thereby alleviating psoriasis induced by Imiquimod.</p>Formule :C29H32O13SCouleur et forme :SolidMasse moléculaire :620.622Protein kinase inhibitor 13
CAS :<p>Protein kinase inhibitor 13 (Compound I-90) functions as a kinase inhibitor, specifically targeting kinases such as PIM-1, CDK-2, GSK-3, and SRC.</p>Formule :C19H20FN5OSCouleur et forme :SolidMasse moléculaire :385.458CGP062464
CAS :<p>CGP062464 is an inhibitor of the tyrosine kinase c-Src, with an IC50 of less than 50 nM. It is utilized in research related to osteoporosis and tumor-induced hypercalcemia.</p>Formule :C18H14N4Couleur et forme :SolidMasse moléculaire :286.331HER2-IN-8
CAS :<p>HER2-IN-8 is an inhibitor of HER-2 that can be used in the study of cancer and inflammation-related diseases.</p>Formule :C26H25F2N9O3Couleur et forme :SolidMasse moléculaire :549.53FGFR2/3-IN-2
CAS :<p>FGFR2/3-IN-2 (compound 10) is an orally active inhibitor targeting FGFR2 and FGFR3. It exhibits IC50 values of 3.7 nM for FGFR2 and 31.2 nM for FGFR3, with a pre-incubation time of 1 hour. FGFR2/3-IN-2 demonstrates selectivity over FGFR1/4 and other kinases, and does not cause diarrhea or increased serum phosphate in vivo. In the SNU-16 gastric cancer model, FGFR2/3-IN-2 can induce tumor stasis or regression.</p>Formule :C29H23FN6O3Couleur et forme :SolidMasse moléculaire :522.53EGFR-IN-159
CAS :<p>EGFR-IN-159 (compound 12) is a dihydropyrimidine and a potent EGFR inhibitor with an IC50 of 29.00 nM. It exhibits dose-dependent inhibition of EGFR and HER2. The compound shows cytotoxicity against MCF-7 breast cancer cells and Vero cells with IC50 values of 16.07 μg/mL and 35.98 μg/mL, respectively. EGFR-IN-159 does not cross the blood-brain barrier (BBB) and demonstrates significant anticancer activity.</p>Formule :C21H23N3O5Couleur et forme :SolidMasse moléculaire :397.424Gamendazole
CAS :<p>Gamendazole is a novel drug candidate for male contraception. It has been shown to reduce fertility in male rats without affecting testosterone levels.</p>Formule :C18H11Cl2F3N2O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :415.19EGFR-IN-149
CAS :<p>EGFR-IN-149 (Compound 3-OH) is an EGFR inhibitor with an IC50 value of 0.42 nM.</p>Formule :C16H15N3OSCouleur et forme :SolidMasse moléculaire :297.375M-COPA
CAS :<p>M-COPA disrupts Golgi, blocks MET & Arf1 activation, and inhibits angiogenesis via VEGFR & NF-kB pathways.</p>Formule :C25H34N2O2Couleur et forme :SolidMasse moléculaire :394.55Clifutinib
CAS :<p>Clifutinib (Compound 9e) is an orally active, selective inhibitor of FMS-like tyrosine kinase 3 (FLT3-ITD) with an IC50 of 15.1 nM. It inhibits FLT3-ITD kinase activity and blocks downstream signaling pathways, including RAS/MAPK, PI3K/AKT, and JAK/STAT5. Clifutinib induces apoptosis in FLT3-ITD mutated acute myeloid leukemia (AML) cells and is a potential candidate for research in relapsed/refractory FLT3-ITD positive AML.</p>Formule :C29H34N4O4Couleur et forme :SolidMasse moléculaire :502.605VEGFR-2/DHFR-IN-2
<p>VEGFR-2/DHFR-IN-2 inhibits VEGFR-2 & DHFR (IC50: 0.623 & 9.085 μM), toxic to C26, HepG2, MCF7 cells (IC50: 3.59-8.38 μM), promising for cancer study.</p>Formule :C21H21NO4Couleur et forme :SolidMasse moléculaire :351.4VEGFR-2-IN-15
<p>VEGFR-2-IN-15 (Compound 14b) is a potent inhibitor of VEGFR-2. VEGFR-2-IN-15 inhibits the growth of HepG2 cells in the Pre-G1 phase and induces apoptosis.</p>Formule :C23H18ClN3O4SCouleur et forme :SolidMasse moléculaire :467.92FGFR1 inhibitor-15
CAS :<p>FGFR1inhibitor-15 (Compound 23) is an FGFR1 inhibitor with an IC50 value of 27 μM, useful for tumor research.</p>Formule :C17H13FN4OCouleur et forme :SolidMasse moléculaire :308.31VEGFR-2-IN-17
<p>VEGFR-2-IN-17 (15a) is a potent VEGFR-2 inhibitor with an IC50 of 67.25 nM, showing significant antitumor effects.</p>Formule :C21H14ClN3O2Couleur et forme :SolidMasse moléculaire :375.81JAK1/TYK2-IN-3
<p>JAK1/TYK2-IN-3, orally active, selectively inhibits TYK2 (IC50: 6 nM), JAK1 (37 nM), JAK2 (140 nM), JAK3 (362 nM), and has anti-inflammatory effects.</p>Couleur et forme :SolidBTK-IN-6
<p>BTK-IN-6, a potent BTK inhibitor, may treat immune, cardiac, cancer, viral, inflammatory, metabolic, and neurological disorders.</p>Formule :C23H22FN5O3Couleur et forme :SolidMasse moléculaire :435.45Brefeldin A 4-O-nicotinate
CAS :<p>Brefeldin A 4-O-nicotinate (CHNQD-01228) is a dual inhibitor of Arf1 and BMX proteins with an IC50 value of 0.22 μM for T24 cell proliferation. It also suppresses T24 cell migration and colony formation in a dose-dependent manner, induces G1 phase arrest, and triggers apoptosis. By targeting BMX proteins, it inhibits the AKT/p-AKT and STAT3/p-STAT3 signaling pathways, while also inhibiting Arf1 proteins to eliminate bladder cancer stem cells and activate antitumor immunity, thus exhibiting anticancer activity. Brefeldin A 4-O-nicotinate is applicable in research related to bladder cancer.</p>Formule :C22H27NO5Couleur et forme :SolidMasse moléculaire :385.453JAK3/BTK-IN-7
CAS :<p>JAK3/BTK-IN-7 (XL-12), characterized as a JAK3/BTK inhibitor, exhibits IC 50 values of 2 nM and 14 nM for JAK3 and BTK respectively. This compound demonstrates anti-inflammatory properties and is applicable in research related to rheumatoid arthritis [1].</p>Formule :C29H30N8O4Couleur et forme :SolidMasse moléculaire :554.6PP487
CAS :<p>PP487 is a dual tyrosine kinase/PI(3)K inhibitor, exhibiting IC50 values of 0.017 μM, 0.072 μM, 0.004 μM, 0.01 μM, 0.55 μM, 0.22 μM, and < 0.01 μM against DNA-PK, mTOR, Hck, Src, EGFR, EphB4, and PDGFR, respectively. It is applicable in cancer research [1].</p>Formule :C14H14BrN5OCouleur et forme :SolidMasse moléculaire :348.2JAK-IN-23
<p>"JAK-IN-23: oral dual JAK/STAT & NF-κB inhibitor; JAK1 (IC50: 8.9 nM), JAK2 (15 nM), JAK3 (46.2 nM); for IBD research."</p>Formule :C23H22Cl2N4OCouleur et forme :SolidMasse moléculaire :441.35FGFR-IN-5
CAS :<p>FGFR-IN-5 is a potent inhibitor of FGFR. FGFR-IN-5 has potential for research in cancer diseases.</p>Formule :C25H22N6O3Couleur et forme :SolidMasse moléculaire :454.48EGFR-IN-35
CAS :<p>EGFR-IN-35, an acrylamide-based EGFR inhibitor, shows promise for EGFR mutation-related cancers like NSCLC.</p>Formule :C25H24ClN7O2Couleur et forme :SolidMasse moléculaire :489.96Pyk2-IN-2
CAS :<p>Pyk2-IN-2 (compound 13j) acts as a Pyk2 inhibitor, exhibiting an IC 50 value of 0.608 μM for FAK kinase [1].</p>Formule :C27H27N7OCouleur et forme :SolidMasse moléculaire :465.55VEGFR-2-IN-12
<p>VEGFR-2-IN-12 (compound 6g), a 2-oxoquinoxalinyl-1,2,4-triazole, is a potent inhibitor of VEGFR-2 (IC50: 0.037 μM). VEGFR-2-IN-12 has anti-tumour effects.</p>Formule :C22H24N6O3SCouleur et forme :SolidMasse moléculaire :452.53CDDD11-8
CAS :<p>CDDD11-8 is an orally administered, highly potent and selective CDK9 and FLT3-ITD inhibitor, with K i values of 8 nM and 13 nM, respectively. It effectively reduces the proliferation of leukemia cell lines, showing particular efficacy against those with the FLT3-ITD mutation [1] [2].</p>Formule :C24H26N6Couleur et forme :SolidMasse moléculaire :398.50EGFR-IN-45
<p>EGFR-IN-45: Strong EGFR/CDK2 inhibitor (IC50s: 0.4 & 1.6 μM), halts cancer cell cycle pre-G1, prompts apoptosis, also targets Topo I/II.</p>Formule :C28H23N7OCouleur et forme :SolidMasse moléculaire :473.53VEGFR-2/DHFR-IN-1
<p>Compound 8b inhibits VEGFR-2/DHFR, combats various bacteria, and fights cancer cells.</p>Formule :C20H18ClNO4Couleur et forme :SolidMasse moléculaire :371.81FLT3/TrKA-IN-1
<p>FLT3/TrKA-IN-1: Potent dual kinase inhibitor for FLT3 & TrKA, promising for AML research.</p>Formule :C28H30N4O2Couleur et forme :SolidMasse moléculaire :454.56DDO-02267
CAS :<p>DDO-02267 is a selective lysine-targeted covalent inhibitor of ALKBH5, with an IC50 value of 0.49 μM. It increases levels of N6-methyladenosine (m6A) and targets the ALKBH5-AXL signaling axis. DDO-02267 serves as a probe for studying the biological function of mRNA demethylases.</p>Formule :C18H12N2O7SCouleur et forme :SolidMasse moléculaire :400.362MK-8457
CAS :<p>MK-8457 is a dual inhibitor of SYK and ZAP70, valuable for rheumatoid arthritis research [1].</p>Formule :C24H25F3N4O3SCouleur et forme :SolidMasse moléculaire :506.54EGFR/HER2-IN-8
<p>EGFR/HER2-IN-8 inhibits EGFR, HER2, DHFR (IC50: 0.45, 0.244, 5.669 μM); useful in cancer research, safe and selective.</p>Formule :C16H16N4O2SCouleur et forme :SolidMasse moléculaire :328.39VEGFR-2-IN-25
CAS :<p>VEGFR-2-IN-25 (compound 5d) is a potent inhibitor of VEGFR-2 (IC50: 12.1 nM).</p>Formule :C24H22N6O2Couleur et forme :SolidMasse moléculaire :426.47LT-850-166
<p>LT-850-166 is a potent inhibitor of FLT3 and has shown efficacy in overcoming a wide range of FLT3 mutations.</p>Formule :C30H29Cl2N7OCouleur et forme :SolidMasse moléculaire :574.5Sacibertinib
CAS :<p>Sacibertinib inhibits Trk, targeting EGFR-TK (EC50 110 nM) & HER2 (EC50 244 nM), with anticancer properties.</p>Formule :C32H31ClN6O4Couleur et forme :SolidMasse moléculaire :599.08EGFR-IN-34
<p>EGFR-IN-34 is a low-toxicity, acrylamide derivative antitumor agent that is a potent inhibitor of EGFR.</p>Formule :C26H27ClN6O2Couleur et forme :SolidMasse moléculaire :490.98HER2-IN-6
CAS :<p>HER2-IN-6, a potent HER2 inhibitor, may target wild/mutant EGFR and HER2-mediated tumors. (Patent WO2021164697A1, compound 11)</p>Formule :C26H32N8O3Couleur et forme :SolidMasse moléculaire :504.58EG31
CAS :<p>EG31 is an EGFR inhibitor that effectively suppresses the proliferation of triple-negative breast cancer (TNBC) cells by inhibiting the EGFR signaling pathway. It demonstrates a GI50 value of 498.90 nM for MDA-MB-231 cells and 740.73 nM for Hs578T cells, while also inducing apoptosis. Additionally, EG31 retains its antiproliferative activity against 5-fluorouracil (5-FU) resistant TNBC cells, with a GI50 of 519.5 nM. EG31 is applicable in research on TNBC resistance.</p>Formule :C30H13Br2N3O6Couleur et forme :SolidMasse moléculaire :671.25JAK/HDAC-IN-3
CAS :<p>JAK/HDAC-IN-3 (13a), a dual inhibitor of JAK and HDAC, exhibits IC50 values of 25.36 nM for JAK2, 0.2 μM for HDAC, and 0.43 μM for HDAC1, respectively [1].</p>Formule :C28H37FN6O5SCouleur et forme :SolidMasse moléculaire :588.69Tyk2-IN-15
CAS :<p>Tyk2-IN-15 (Compound 97) is a selective inhibitor of tyrosine kinase 2 (Tyk2) with an IC50 value ≤ 10 nM for Tyk2-JH2. It is utilized in the research of inflammatory and autoimmune diseases [1].</p>Formule :C21H25F2N7OCouleur et forme :SolidMasse moléculaire :429.47EGFR-IN-24
<p>EGFR-IN-24 is a potent inhibitor of EGFR and inhibits EGFR (del19/T790M/C797S) and EGFR (L858R/T790M/C797S).</p>Formule :C30H35FN6O3Couleur et forme :SolidMasse moléculaire :546.64Tyk2-IN-14
CAS :<p>Tyk2-IN-14, a small molecule inhibitor of TYK2, is significant in treating inflammatory diseases and conditions linked to hypersecretion of IFNa and interferons [1].</p>Formule :C22H21N9O2Couleur et forme :SolidMasse moléculaire :443.46EGFR-IN-160
CAS :<p>EGFR-IN-160 is an EGFR inhibitor with IC50 values of 1.62, 0.49, and 0.98 μM for EGFRWT, EGFRT790M, and EGFRL858R/T790M/C797S, respectively. It can induce cell cycle arrest at the G2/M and S phases and apoptosis (Apoptosis) in NCI-H522 cells, demonstrating anticancer properties. Additionally, EGFR-IN-160 exhibits antioxidant activity against DPPH (IC50: 12.11 µM) and H2O2 (IC50: 8.89 µM).</p>Formule :C15H12N2O4Couleur et forme :SolidMasse moléculaire :284.27JAK1/TYK2-IN-4
CAS :<p>JAK1/TYK2-IN-4 serves as a dual inhibitor targeting both JAK and TYK2, displaying IC50 values of 39 nM and 21 nM, respectively. It is also orally bioavailable [1].</p>Formule :C17H23N7OCouleur et forme :SolidMasse moléculaire :341.41Tyk2-IN-17
CAS :<p>Tyk2-IN-17 (compound 185) effectively inhibits TYK2 [1].</p>Formule :C20H20F2N8OCouleur et forme :SolidMasse moléculaire :426.42PNU-145156E
CAS :<p>PNU-145156E is a noncytotoxic molecule inhibiting growth and angiogenic factors, suppress tumor angiogenesis, support anti-angiogenic research strategies.</p>Formule :C45H40N10O17S4Couleur et forme :SolidMasse moléculaire :1121.12Lazertinib mesylate
CAS :<p>Lazertinib (mesylate) (YH25448 (mesylate); GNS-1480 (mesylate)) is an orally active EGFR inhibitor capable of crossing the blood-brain barrier. It suppresses the p-EGFR, p-AKT, and p-ERK signaling pathways, leading to apoptosis. Lazertinib (mesylate) demonstrates antitumor activity in the H1975-luc BM xenograft model in mice and is applicable for researching non-small cell lung cancer.</p>Formule :C31H38N8O6SMasse moléculaire :650.75CEE321
CAS :<p>CEE321 is an effective pan-JAK inhibitor with an IC50 of 54 nM. It effectively inhibits biomarkers associated with atopic dermatitis.</p>Formule :C18H16ClN5OCouleur et forme :SolidMasse moléculaire :353.806BTK-IN-7
<p>BTK-IN-7 is a potent inhibitor for BTK with 4.0 nM IC50, highly selective over ITK and EGFR, showing strong antitumor activity.</p>Formule :C30H32N6O4Couleur et forme :SolidMasse moléculaire :540.61Ki11502
CAS :<p>Ki11502 is a multi-target receptor tyrosine kinase (RTK) inhibitor that selectively inhibits the activity of PDGFβ/α receptors (with an IC50 of less than 10 nM). It specifically suppresses PDGFβ receptor phosphorylation, proliferation, and proteoglycan synthesis in human vascular smooth muscle cells. Additionally, Ki11502 induces apoptosis and exhibits significant antiproliferative effects against specific leukemia subgroups, including those with Imatinib-resistant mutations. It is particularly suitable for studying the role of PDGF in vascular diseases and the involvement of proteoglycans in atherosclerosis.</p>Formule :C26H23N3O4SMasse moléculaire :473.54EGFR/HER2-IN-6
<p>EGFR/HER2-IN-6 is a dual inhibitor of EGFR, HER2, and DHFR with IC50s: 0.122, 0.078, and 0.585 μM, showing anticancer potential and selectivity.</p>Formule :C18H21N5O3SCouleur et forme :SolidMasse moléculaire :387.46FGFR4-IN-6
<p>FGFR4-IN-6: covalent, reversible FGFR4 blocker, 5.4 nM IC50, good oral bioavailability, reduces Hep3B2.1-7 tumors in mice, low toxicity.</p>Formule :C31H33N7O4Couleur et forme :SolidMasse moléculaire :567.64FGFR4-IN-9
<p>FGFR4-IN-9 is a selective inhibitor of FGFR4 (IC50: 75.3 nM) that effectively inhibits the growth and angiogenesis of hepatocellular carcinoma cells.</p>Formule :C24H22ClF3N4O4Couleur et forme :SolidMasse moléculaire :522.9EGFR-IN-17
<p>EGFR-IN-17: potent, selective EGFR inhibitor, IC50 of 0.2 nM, overcomes C797S drug resistance.</p>Formule :C27H31ClN7O3PCouleur et forme :SolidMasse moléculaire :568.01E7090 succinate
CAS :<p>E7090 succinate inhibits FGFR1, FGFR2, and FGFR3 with IC50: 0.71, 0.50, 1.2 nM; less so FGFR4 at 120 nM.</p>Formule :C76H92N10O24Couleur et forme :SolidMasse moléculaire :1529.60Antiallergic agent-1
<p>Antiallergic agent-1, an Src family kinase inhibitor, is a new and valuable lead compound with potential as an anti-allergic agent.</p>Formule :C27H19F6N5OCouleur et forme :SolidMasse moléculaire :543.46TTT 3002
CAS :<p>TTT 3002: oral FLT3 inhibitor for AML research, blocks D835 mutations, potent at 0.2 nM IC50.</p>Formule :C27H23N5O3Couleur et forme :SolidMasse moléculaire :465.50JAK2 JH2 binder-1
CAS :<p>JAK2 JH2 binder-1: potent, selective, Ki=37.1 nM, potential for studying myeloproliferative neoplasms.</p>Formule :C29H25N7O6SCouleur et forme :SolidMasse moléculaire :599.62EGFR-IN-18
<p>EGFR-IN-18 strongly inhibits L858R/T790M/C797S mutant EGFR (4.9 nM) and also targets wild-type EGFR (47 nM).</p>Formule :C33H28N6O3SCouleur et forme :SolidMasse moléculaire :588.68EGFR-IN-62
<p>EGFR-IN-62: IC50 of 10-242 nM for various EGFR mutations, blocks A549/H1975 cell cycle, induces apoptosis, and inhibits cell motility and proliferation.</p>Formule :C30H33N9O2Couleur et forme :SolidMasse moléculaire :551.64PF-06463922 acetate
CAS :<p>PF-06463922 acetate: ALK/ROS1 inhibitor, brain- penetrable, active vs crizotinib-resistant mutants, in NSCLC trials.</p>Formule :C23H23FN6O4Couleur et forme :SolidMasse moléculaire :466.46FGFR1 inhibitor-6
<p>FGFR1 inhibitor-6, IC50: 16.31 nM, blocks cell cycle at pro-G1/G2/M and induces apoptosis.</p>Formule :C27H19N5O4S2Couleur et forme :SolidMasse moléculaire :541.6ALK-IN-23
<p>ALK-IN-23 inhibits ALK (IC50: 1.6-0.71 nM), hinders cancer cell spread, forms colonies in vitro, and reduces tumors in mice with low toxicity.</p>Formule :C26H29ClN8O3SCouleur et forme :SolidMasse moléculaire :569.08BTK-IN-10
CAS :<p>BTK-IN-10 is a potent inhibitor of BTK, acting on wild-type BTK (IC50<5 nM) or mutant BTK (C481S) (IC50<5 nM).</p>Formule :C25H24F2N4O2Couleur et forme :SolidMasse moléculaire :450.48VEGFR-2-IN-14
<p>VEGFR-2-IN-14 (Compound 5) is a potent inhibitor of VEGFR-2, which inhibits the growth of HepG2 cells in the Pre-G1 phase and induces apoptosis.</p>Formule :C24H23N3O3SCouleur et forme :SolidMasse moléculaire :433.52NSC381467
CAS :<p>NSC381467: Potent, oral EGFR-TK inhibitor with strong antiproliferative effects, promising for cancer research.</p>Formule :C20H16O7Couleur et forme :SolidMasse moléculaire :368.34AZD0424
CAS :<p>AZD0424: oral Src/Abl kinase inhibitor; potential anticancer; induces apoptosis, cell cycle arrest in lymphoma.</p>Formule :C25H29ClN6O5Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :528.99Ten01
<p>Ten01 exhibits a 5.0 nM inhibition of JAK1 kinase.</p>Formule :C18H20F6N4OCouleur et forme :SolidMasse moléculaire :422.37VVD-118313
CAS :<p>VVD-118313 (5a) is a potent JAK1 inhibitor targeting allosteric cysteine, blocking cytokine signaling for cancer research.</p>Formule :C19H22Cl2N2O3SCouleur et forme :SolidMasse moléculaire :429.36FGFR3-IN-4
CAS :<p>FGFR3-IN-4 is a selective inhibitor targeting FGFR3, demonstrating an IC50 value of under 50 nM.</p>Formule :C26H24ClN7OCouleur et forme :SolidMasse moléculaire :485.97Hypothemycin
CAS :<p>Hypothemycin, a fungal polyketide, inhibits multiple kinases (VEGFR, MEK, FLT-3, PDGFR, ERK) with Kis ranging from 10 nM to 2.4 μM.</p>Formule :C19H22O8Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :378.37EGFR-IN-23
CAS :<p>EGFR-IN-23, identified as compound 8 in WO2021244502A1, is a potent EGFR tyrosine kinase inhibitor (TKI) demonstrating an inhibitory concentration (IC50) of 8.</p>Formule :C36H44BrN10O3PCouleur et forme :SolidMasse moléculaire :775.68Multi-kinase-IN-1
CAS :<p>Multi-kinase-IN-1, a powerful kinase inhibitor, exhibits antitumor properties by inducing cell apoptosis.</p>Formule :C35H36F2N6O6SCouleur et forme :SolidMasse moléculaire :706.76JAK3/BTK-IN-3
CAS :<p>JAK3/BTK-IN-3: strong dual JAK3/BTK suppressor, promising for autoimmune disease research.</p>Formule :C22H28N8OCouleur et forme :SolidMasse moléculaire :420.51BTK inhibitor 18
<p>BTK inhibitor 18 is a selective, potent, covalent, orally active Btk inhibitor (IC50: 142 nM) that exhibits anti-inflammatory effects.</p>Formule :C29H25N5O4S2Couleur et forme :SolidMasse moléculaire :571.67JAK1-IN-9
CAS :<p>JAK1-IN-9 (compound 23a) is a potent, selective inhibitor of JAK1, demonstrating an IC50 of 72 nM.</p>Formule :C16H13IN6Couleur et forme :SolidMasse moléculaire :416.22FAK inhibitor 6
CAS :<p>Compound 26F: potent enzyme inhibitor (IC50=28.2nM), low cytotoxicity (IC50=3.32μM), induces dose-dependent apoptosis in MDA-MB-231, blocks G0/G1 phase.</p>Formule :C25H24FN5O2SCouleur et forme :SolidMasse moléculaire :477.55JAK2-IN-11
CAS :<p>JAK2-IN-11 (Example 6) is a JAK2 kinase inhibitor with potent antitumor activity, exhibiting an IC50 of ≤10 nM against JH2 BIND WT/V617F. This compound effectively suppresses tumor growth.</p>Formule :C31H31F3N8O4Couleur et forme :SolidMasse moléculaire :639.64ALK/PI3K/AKT-IN-1
CAS :<p>ALK/PI3K/AKT-IN-1 (Compound 45) effectively inhibits the proliferation of cancer cell lines A549, H1975, and PC9, with IC50 values of 0.44, 0.83, and 1.51 μM, respectively. This compound enhances the expression of p21 and p27, and decreases the activity of CDK2 and p-Rb, causing cell cycle arrest at the G1 phase. It suppresses the ALK/PI3K/AKT signaling pathway, promotes mitochondrial membrane potential depolarization, and induces apoptosis in A549 cells. Furthermore, ALK/PI3K/AKT-IN-1 inhibits the formation and growth of A549 cell spheres.</p>Formule :C25H20FN5O2SCouleur et forme :SolidMasse moléculaire :473.522FAK-IN-2
<p>FAK-IN-2: potent oral FAK inhibitor, IC50 35 nM, reduces tumor growth, migration, and induces cell death.</p>Formule :C28H31ClN8O3Couleur et forme :SolidMasse moléculaire :563.05CDD-1115
CAS :<p>CDD-1115 is a potent and selective BMPR2 inhibitor, with an IC50 of 1.8 nM and a Kiapp of 6.2 nM. It effectively suppresses gene expression mediated by bone morphogenetic proteins (BMPs). BMPs regulate cellular processes in various tissue types, such as the kidneys, skeletal muscle, heart, and reproductive organs, and can induce ectopic bone formation.</p>Formule :C32H30N6O3Couleur et forme :SolidMasse moléculaire :546.619VEGFR-2-IN-5 hydrochloride
<p>VEGFR-2-IN-5 hydrochloride is an effective VEGFR2 inhibitor.</p>Formule :C19H25ClN8Couleur et forme :SolidMasse moléculaire :400.91JBJ-09-063
CAS :<p>JBJ-09-063: EGFR inhibitor, IC50s 0.147-0.396 nM for various mutants; hinders EGFR/Akt/ERK1/2 phosphorylation; targets TKI-sensitive/resistant lung cancer.</p>Formule :C31H29FN4O3SCouleur et forme :SolidMasse moléculaire :556.65FAK-IN-6
<p>FAK-IN-6: Potent FAK inhibitor (IC50=1.415 nM), anti-cancer, for pancreatic studies.</p>Formule :C25H31ClN5O6PSCouleur et forme :SolidMasse moléculaire :596.04ALK-IN-31
CAS :<p>ALK-IN-31 (Compound Ld-10) is an orally active ALK inhibitor with an IC50 of 1135 nM. It demonstrates excellent antiproliferative activity against lung cancer cells H2228, with an IC50 value of 1.35 μM. ALK-IN-31 induces apoptosis and arrests cell proliferation at the G0/G1 phase by affecting mitochondrial function. It exhibits antitumor effects by downregulating the expression of p-AKT and p-mTOR in the PI3K-AKT-mTOR signaling pathway downstream of ALK. This compound is applicable for research into non-small cell lung cancer (NSCLC).</p>Formule :C30H33N5O2SCouleur et forme :SolidMasse moléculaire :527.68RGB-286638
CAS :<p>RGB-286638 inhibits multiple CDKs and GSK-3β, TAK1, Jak2, MEK1 with IC50s as low as 1-54 nM.</p>Formule :C29H37Cl2N7O4Couleur et forme :SolidMasse moléculaire :618.55LSD1/EGFR-IN-1
CAS :<p>LSD1/EGFR-IN-1 (compound L-1) is an effective inhibitor of LSD1, EGFRT790M/L858R, and EGFRL858R/T790M/C797S, with IC50 values of 6.24, 2.06, and 5.01 μM, respectively. This compound plays a significant role in cancer research.</p>Formule :C21H20ClN3O4Couleur et forme :SolidMasse moléculaire :413.854JNJ-47117096
CAS :<p>JNJ-47117096 is a potent and selective MELK inhibitor with an IC50 of 23 nM, and it also exhibits strong activity against Flt3 with an IC50 of 18 nM.</p>Formule :C21H22N4O2Couleur et forme :SolidMasse moléculaire :362.425EGFR-IN-48
<p>EGFR-IN-48: potent EGFR inhibitor, oral, IC50: 0.193-66.7 nM, blocks EGFR mutants & BaF3/PC-9 cell proliferation.</p>Couleur et forme :SolidBMS-066
CAS :<p>BMS-066 is an IKKβ/Tyk2 pseudokinase inhibitor. With IC50s of 9 nM and 72 nM, respectively.</p>Formule :C19H21N7O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :379.42FGFR4-IN-10
<p>FGFR4-IN-10 (compound 5a) is a potent, selective FGFR4 inhibitor with IC50 of 70.7 nM, sparing FGFR1-3.</p>Formule :C20H19F3N6O3Couleur et forme :SolidMasse moléculaire :448.4TYK2 ligand 2
CAS :<p>TYK2ligand 2 is the TYK2 ligand of PROTACTYD-68. TYD-68 is a highly potent and selective CRBN-recruiting TYK2 PROTAC degrader with a DC50 value of 0.42 nM.</p>Formule :C24H20FN7O4Couleur et forme :SolidMasse moléculaire :489.458FAK-IN-4
<p>FAK-IN-4 (Compound 7d) has anticancer activities that can induce cell apoptosis. FAK-IN-4 is potential inhibitor of FAK [1].</p>Formule :C20H22N4OCouleur et forme :SolidMasse moléculaire :334.41BTK-IN-15
<p>BTK-IN-15: Oral BTK inhibitor, IC50 0.7 nM, induces cancer cell apoptosis, selective with anti-tumor effects.</p>Formule :C28H24FN5O2Couleur et forme :SolidMasse moléculaire :481.52FGFR-IN-6
CAS :<p>FGFR-IN-6 (Compound 5) is an FGFR inhibitor.</p>Formule :C23H22N6O3Couleur et forme :SolidMasse moléculaire :430.46Tyrphostin 63
CAS :<p>Tyrphostin 63 (compound 13) is an epidermal growth factor receptor (EGFR) inhibitor, with an IC50 of 375 μM and a Ki of 123 μM.</p>Formule :C10H8N2OCouleur et forme :SolidMasse moléculaire :172.183iBFAR2
CAS :<p>iBFAR2, an inhibitor of BFAR, restores the CD8+ tumor-resident memory T cell subset against solid tumors. It promotes the binding of JAK2-STAT1 and enhances the phosphorylation of STAT1.</p>Formule :C19H15F3N2O2Couleur et forme :SolidMasse moléculaire :360.33Andamertinib
CAS :<p>Andamertinib is an EGFR inhibitor with antitumor activity.</p>Formule :C31H36N8O3Couleur et forme :SolidMasse moléculaire :568.669EGFR/BRAF-IN-1
<p>EGFR/BRAF-IN-1 inhibits EGFR/BRAF (BRAFV600E IC50: 45 nM, GI50: 35 nM) and has antioxidant properties.</p>Formule :C26H28ClN3O4Couleur et forme :SolidMasse moléculaire :481.97(S)-3-Hydroxy Midostaurin
CAS :<p>(S)-3-Hydroxy Midostaurin is a potent inhibitor of kinases(IC50 of <400 nM for 13 kinases (VEGFR-2, TRK-A, FLT3, et)).</p>Formule :C35H30N4O5Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :586.64HER2-IN-7
CAS :<p>HER2-IN-7 is a potent HER2 inhibitor with potential for researching ErbB-related diseases, especially cancer.</p>Formule :C28H26F3N7O3Couleur et forme :SolidMasse moléculaire :565.55EGFR-IN-139
CAS :<p>EGFR-IN-139 (compound PD 18) is an EGFR inhibitor with IC50 values of 12.88 nM (wild type), 10.84 nM (L858R/T790M), and 42.68 nM (L858R/T790M/C797S). It demonstrates significant anticancer activity against the A549 and H1975 cancer cell lines, which express high levels of EGFR. EGFR-IN-139 exhibits strong selectivity for cancer cells and can be utilized in research on non-small cell lung cancer (NSCLC).</p>Formule :C27H25ClN2O4Couleur et forme :SolidMasse moléculaire :476.951VEGFR-2-IN-10
<p>VEGFR-2-IN-10 has enhanced antiangiogenic potency against VEGFR2 phosphorylation induced by VEGF with an IC50 value of 0.7 μM and no cytotoxic effects.</p>Formule :C20H21N3O2Couleur et forme :SolidMasse moléculaire :335.4Squalamine
CAS :<p>Squalamine is an aminosterol compound, with potent broad spectrum antiviral activity.</p>Formule :C34H65N3O5SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :627.96MM-589
CAS :<p>MM-589 is a potent WD repeat domain 5 (WDR5) inhibitor and mixed lineage leukemia (MLL) protein-protein interaction.</p>Formule :C28H44N8O5Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :572.70Lomonitinib
CAS :<p>Lomonitinib is a potent and selective pan-FLT3/IRAK4 inhibitor with antitumor properties. It shows promise for research in myeloid leukemia.</p>Formule :C27H24N4O2Couleur et forme :SolidMasse moléculaire :436.505(Rac)-PT2399
CAS :<p>(Rac)-PT2399 is a potent and specific inhibitor of hypoxia-inducible factor 2a (HIF-2α)(IC50 of 0.01 μM).</p>Formule :C17H10F5NO4SCouleur et forme :SolidMasse moléculaire :419.32VEGFR-2-IN-26
CAS :<p>VEGFR-2-IN-26 inhibits VEGFR-2 (IC50: 15.5 nM), combating various cancers' cell growth.</p>Formule :C24H19F3N6O2Couleur et forme :SolidMasse moléculaire :480.44EGFR-IN-146
CAS :<p>EGFR-IN-146 is an EGFR inhibitor that suppresses the EGFR signaling pathway and improves insulin sensitivity by activating the AMPK pathway. It effectively reduces blood glucose levels and body weight, showing great potential in the study of diabetes and obesity.</p>Formule :C20H16N4Couleur et forme :SolidMasse moléculaire :312.368ALKBH5-IN-3
CAS :<p>ALKBH5-IN-3 (Compound 20m) is an efficacious and selective inhibitor of ALKBH5, exhibiting an IC50 value of 21 nM. It effectively stabilizes ALKBH5 in HepG2 cells and enhances m6A levels in intact cells.</p>Formule :C11H7F3N2O3Couleur et forme :SolidMasse moléculaire :272.18MTX-216
CAS :<p>MTX-216 is an ATP-competitive inhibitor targeting both PI3K and EGFR. It simultaneously inhibits Ki-67 and ribosomal S6 phosphorylation, inducing apoptosis in NF1LOF cells. Additionally, MTX-216 suppresses SYK kinase activity with an IC50 of 281 nM. This compound is applicable for melanoma research.</p>Formule :C22H14Cl2FN5O2SCouleur et forme :SolidMasse moléculaire :502.348JAK-IN-19
<p>JAK-IN-19 inhibits JAK (pIC50: 7.2, 7.7), less so for VEGFR2 (7.0) and Aurora B (5.8).</p>Formule :C26H36FN5O2Couleur et forme :SolidMasse moléculaire :469.59BMS-986143
CAS :<p>BMS-986143: oral BTK inhibitor, IC50=0.26 nM, potential for autoimmune research, also targets TEC, BLK, BMX, TXK, YES1, ITK.</p>Formule :C31H24Cl2N4O4Couleur et forme :SolidMasse moléculaire :587.45JAK3/BTK-IN-4
CAS :<p>JAK3/BTK-IN-4, a dual inhibitor for JAK3/BTK, shows synergy in autoimmune disease treatment. (Patent WO2021147953A1, compound 003)</p>Formule :C21H25ClN8OCouleur et forme :SolidMasse moléculaire :440.93I194496
CAS :<p>I194496 is an effective inhibitor of cystathionine γ-lyase (CSE) with an IC50 value of 0.79 mM. It inhibits the growth of human TNBC cells by dual targeting the PI3K/Akt and Ras/Raf/ERK pathways. Additionally, I194496 suppresses the metastasis of human TNBC cells by downregulating the Anxa2/STAT3 and VEGF/FAK/Paxillin signaling pathways.</p>Formule :C28H23F2N5O5SCouleur et forme :SolidMasse moléculaire :579.58FLT3-IN-13
<p>FLT3-IN-13 inhibits topoisomerase II/FLT3 in leukemia with IC50 of 2.26 μM, causes G2/M arrest, and promotes apoptosis.</p>Formule :C20H14N4O2Couleur et forme :SolidMasse moléculaire :342.35SYHA1815
CAS :<p>SYHA1815, an orally active RET inhibitor (IC50=0.9 nmol/L), demonstrates antitumor activity. It exhibits greater selectivity for RET over KDR (IC50=15.9 nmol/L). SYHA1815 operates by downregulating c-Myc, arresting the G1 cell cycle, and inhibiting RET-driven cell proliferation.</p>Formule :C27H26ClF4N5OCouleur et forme :SolidMasse moléculaire :547.98FLT3/ITD-IN-1
<p>FLT3/ITD-IN-1 inhibits FLT3-ITD with IC50s: 38.2 nM (FLT3) and 144.1 nM (ITD), and fights acute myeloid leukemia.</p>Formule :C19H22N6O2Couleur et forme :SolidMasse moléculaire :366.42CLM3
CAS :<p>CLM3, a pyrazolopyrimidine derivative, functions as a multitargeted tyrosine kinase inhibitor. It exhibits antiproliferative and proapoptotic activities on endothelial and cancer cells, activities that are synergistically enhanced by SN38. The primary mechanism of action for CLM3 involves the inhibition of phosphorylation in tyrosine kinases such as VEGFR-2, EGFR, and RET, along with their associated signaling pathways.</p>Formule :C21H21N5Couleur et forme :SolidMasse moléculaire :343.43Multi-kinase inhibitor 3
CAS :<p>Multi-kinase inhibitor 3 (compound 12) is an orally active and effective multikinase (multikinase) inhibitor, demonstrating potent IC50 values against FLT1/VEGFR1, KDR/VEGFR2, FLT4/VEGFR3, FLT3, PDGFRα, and PDGFRβ, at 1.59, 1.23, 1.19, 0.59, 0.22, and 1.15 nM respectively. This compound exhibits anti-proliferative and anticancer activities.</p>Formule :C26H26N6O2Couleur et forme :SolidMasse moléculaire :454.52EGFR/HER2-IN-5
<p>EGFR/HER2-IN-5: Irreversible, oral dual EGFR inhibitor, IC50 0.6 nM, targets L858R/T790M mutations, anti-tumor in vivo for lung cancer study.</p>Couleur et forme :SolidSILA-123
CAS :<p>SILA-123, an inhibitor of FLT3 (FLT3-WT: IC50=2.1 nM; FLT3-ITD: IC50=1.0 nM), induces cell apoptosis by hindering the cell cycle progression at the G0/G1 phase through the suppression of FLT3 phosphorylation and its downstream signaling pathways. This compound is utilized in the study of acute myeloid leukemia.</p>Formule :C24H25N5O2Couleur et forme :SolidMasse moléculaire :415.49HER2-IN-9
<p>HER2-IN-9, an oral HER2 inhibitor (IC50: 0.03 μM), hinders growth and spread of HER2+ breast cancer.</p>Formule :C19H14BrF3N2OCouleur et forme :SolidMasse moléculaire :423.23BML-265
CAS :<p>BML-265 is a potent inhibitor of EGFR tyrosine kinase (EGFR tyrosine kinase). It disrupts Golgi apparatus integrity in human cells and hinders the transport of secretory proteins across various substances. In contrast, BML-265 does not affect the integrity and transport of the Golgi apparatus in rodent cells.</p>Formule :C18H15N3O2Couleur et forme :SolidMasse moléculaire :305.331YSY01A
CAS :<p>YSY01A is a proteasome inhibitor that suppresses cancer cell survival by inducing apoptosis (Apoptosis). It demonstrates IC50 values against various cell lines such as HEK293T, A549, MCF-7, MGC-803, and PC-3M with values of 51.01, 9.21, 5.21, 8.9, and 35.4 nM respectively. Additionally, YSY01A serves as a degrader of gp130 and JAK2, eliminating constitutive STAT3 signaling in human A549 lung cancer cells by downregulating gp130 and JAK2. YSY01A holds potential for research in cancer therapeutics.</p>Formule :C29H38BN5O5Couleur et forme :SolidMasse moléculaire :547.45VEGFR-2-IN-11
<p>VEGFR-2-IN-11 is a potent inhibitor of VEGFR-2 (IC50: 60.27 nM) with an IC50 value of 60.27 nM, which induces apoptosis and has anticancer activity.</p>Formule :C29H22BrN5SCouleur et forme :SolidMasse moléculaire :552.49Multi-kinase inhibitor 4
CAS :<p>Multi-kinase inhibitor 4 (compound 14) serves as an orally effective inhibitor targeting FLT1, KDR, FLT3, FLT4, PDGFRα, and PDGFRβ, exhibiting IC50 values of 1.97 nM, 1.04 nM, 0.33 nM, 1.44 nM, 0.18 nM, and 0.89 nM respectively. This compound plays a crucial role in cancer research.</p>Formule :C25H24N6O2Couleur et forme :SolidMasse moléculaire :440.50ERBB agonist-1
CAS :<p>ERBB agonist-1 (Compound EF-1) is an ERBB4 agonist that activates the ERBB4 signaling pathway by inducing ERBB4 receptor dimerization, with an EC50 of 10.5 μM. It promotes phosphorylation of Akt and ERK1/2, reduces collagen expression in cardiac fibroblasts, and inhibits H2O2-induced cardiomyocyte death and Ang II-induced cardiac hypertrophy. Furthermore, ERBB agonist-1 can prevent myocardial fibrosis and demonstrates cardioprotective effects in mouse models.</p>Formule :C24H25N3O2SCouleur et forme :SolidMasse moléculaire :419.539FAK-IN-26
CAS :<p>FAK-IN-26 is a blood-brain barrier-penetrating inhibitor of Focal Adhesion Kinase (FAK) with an IC50 of 0.87 nM. It significantly reduces tumor cell viability, cancer stem cell activity, and cell migration in A549 and SKOV-3 cell lines. FAK-IN-26 exhibits potent anticancer activity, achieving tumor inhibition rates of 59.15% and 57.9% in A549 and SKOV-3 tumor mouse models, respectively.</p>Formule :C20H19BrFN5O2Couleur et forme :SolidMasse moléculaire :460.30AFP464 free base
CAS :<p>AFP464 (NSC710464) free base is an active HIF-1α inhibitor (IC50: 0.25 μM) and a potent aryl hydrocarbon receptor (AhR) activator.</p>Formule :C22H23F3N4O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :448.44(-)-Cevimeline hydrochloride hemihydrate
<p>(-)-Cevimeline HCl hemihydrate, a muscarinic agonist, treats Sjogren's xerostomia. Quick absorption, species-dependent metabolism.</p>Formule :C10H19ClNO1·5SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :244.78Tyk2-IN-3
CAS :<p>Tyk2-IN-3 is an inhibitor of Tyk2 pseudokinase (IC50: 485 nM).</p>Formule :C25H24N6O3S2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :520.63HDHD4-IN-1
CAS :<p>HDHD4-IN-1 (compound 3) is an inhibitor of N-acetylneuraminate-9-phosphate phosphatase (HDHD4) with an IC50 value of 11 μM. It is utilized in the research of neurological disorders.</p>Formule :C12H22NO11PCouleur et forme :SolidMasse moléculaire :387.28(3S,4R)-Tofacitinib
CAS :<p>(3S,4R)-Tofacitinib is an less active enantiomer of Tofacitinib. Tofacitinib is a JAK3 inhibitor(IC50 : 1 nM).</p>Formule :C16H20N6ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :312.37VEGFR-2-IN-16
<p>VEGFR-2-IN-16 (Compound 15b) is a potent inhibitor of VEGFR-2 (IC50: 86.36 nM) that exhibits antitumour effects.</p>Formule :C21H13Cl2N3O2Couleur et forme :SolidMasse moléculaire :410.25PF-06263276
CAS :<p>PF-06263276 selectively inhibits pan-JAK with IC50: JAK1 (2.2 nM), JAK2 (23.1 nM), JAK3 (59.9 nM), TYK2 (29.7 nM).</p>Formule :C31H31FN8O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :566.63EGFR-IN-161
CAS :<p>EGFR-IN-161 (Compound DD-8) is a potent and reversible inhibitor of the L858R/T790M/C797S mutant EGFR kinase, with an IC50 value of 0.87 nM. EGFR-IN-161 effectively inhibits tumor cell apoptosis, G1 phase arrest, and migration.</p>Formule :C33H36Cl2N8O2Couleur et forme :SolidMasse moléculaire :647.597MM-589 TFA
CAS :<p>MM-589 TFA is a potent WD repeat domain 5 (WDR5)inhibitor and mixed lineage leukemia (MLL) protein-protein interaction.</p>Formule :C30H45F3N8O7Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :686.72Siphonaxanthin
CAS :<p>Siphonaxanthin is a carotenoid found in green algae, known for targeting the death receptor 5 (DR5) on cancer cells to induce apoptosis. In human leukemia HL-60 cells, it increases DR5 expression, reduces Bcl-2 levels, and activates caspase-3. It also inhibits fibroblast growth factor receptor-1 (FGFR-1) signaling in endothelial cells. Siphonaxanthin suppresses the proliferation, migration, and tubular formation of human umbilical vein endothelial cells (HUVECs), as well as the growth of microvessels in rat aorta rings. Additionally, it has anti-inflammatory properties by blocking the translocation of high-affinity IgE receptors (FcεRI) to lipid rafts in mast cells. Siphonaxanthin shows potential for research into diseases such as cancer, diabetic retinopathy, and rheumatoid arthritis.</p>Formule :C40H56O4Couleur et forme :SolidMasse moléculaire :600.87W23-1006
CAS :<p>W23-1006 is a selective covalent ALKBH5 inhibitor. It binds to the ALKBH5 C200 residue with an IC50 value of 3.848 μM. The inhibitory activity of W23-1006 is approximately 30 times stronger than that of FTO and 8 times greater than that of ALKBH3. W23-1006 is applicable for research in triple-negative breast cancer (TNBC).</p>Formule :C17H12BrN3O5Couleur et forme :SolidMasse moléculaire :418.198EGFR/HER2/DHFR-IN-1
<p>Potent EGFR/HER2/DHFR inhibitor for MCF-7 breast cancer; IC50: 0.153/0.108/0.291 μM; arrests G1/S phase, triggers apoptosis.</p>Formule :C14H11BrN4O2SCouleur et forme :SolidMasse moléculaire :379.23Protein kinase inhibitor 11
CAS :<p>Protein kinase inhibitor 11 (Compound I-96) is an agent that inhibits the activity of PIM-1, CDK-2, GSK-3, and SRC. It shows potential for research in cancer, autoimmune diseases, and neurodegenerative disorders.</p>Formule :C21H18FN5O2SCouleur et forme :SolidMasse moléculaire :423.463JP-153
CAS :<p>JP-153 is an inhibitor of Src-FAK-Paxillin signaling. It suppresses Src-dependent phosphorylation of paxillin (Y118) and subsequent activation of Akt (S473). JP-153 reduces VEGF-induced migration and proliferation of retinal endothelial cells and is applicable in the study of neovascular eye diseases.</p>Formule :C21H19NO5Couleur et forme :SolidMasse moléculaire :365.379Dual Cathepsin L/JAK-IN-1
CAS :<p>DualCathepsinL/JAK-IN-1 (Compound A8) serves as a dual inhibitor of Cathepsin L (CTSL) and JAK, exhibiting IC50 values of 0.68 μM for CTSL and 337.1 nM, 5.251 nM, 27.29 nM, and 172.6 nM for JAK1/2/3 and TYK2, respectively. This compound effectively prevents the activation of MAPK, NF-κB, and JAK/STAT signaling pathways, leading to significant anti-inflammatory therapeutic effects. DualCathepsinL/JAK-IN-1 is applicable in research on acute lung injury (ALI).</p>Formule :C19H18ClN5Couleur et forme :SolidMasse moléculaire :351.833Protein kinase inhibitor 10
CAS :<p>Protein kinase inhibitor 10 is a protein kinase inhibitor with IC50 values of 28.9 μM, 13.6 μM, and 2.41 μM for TAM receptors, FAK, and KIT, respectively. It can inhibit abnormal and excessive cell proliferation, showing potential for research in the field of cancer treatment.</p>Formule :C14H9FN6S2Couleur et forme :SolidMasse moléculaire :344.39GNE-431
CAS :<p>GNE-431: potent, selective noncovalent Btk inhibitor, IC50=3.2 nM; effective against C481R, T474I, T474M mutants, may counter ibrutinib resistance.</p>Formule :C30H32N10O2Couleur et forme :SolidMasse moléculaire :564.64EGFR/HER2-IN-4
<p>EGFR/HER2-IN-4: oral, irreversible dual EGFR inhibitor (IC50: 0.6 nM), targets L858R/T790M mutations, potent anti-lung cancer effects in vivo.</p>Couleur et forme :SolidRET-IN-14
CAS :<p>RET-IN-14 inhibits RET (IC50: <0.51-9.3 nM) & BTK (C481S) (IC50: 9.2-15 nM), promising for tumor research.</p>Formule :C24H23FN8O4Couleur et forme :SolidMasse moléculaire :506.49FLT3-ITD-IN-3
CAS :<p>FLT3-ITD-IN-3 (13v) is an orally active inhibitor of FLT3-ITD (internal tandem duplication of FLT3), which works by blocking FLT3 signaling. This inhibition leads to cell cycle arrest in the G0/G1 phase and induces apoptosis. The compound is currently employed in studies related to acute myeloid leukemia (AML).</p>Formule :C27H21ClF2N6O5Couleur et forme :SolidMasse moléculaire :582.943AKN-028 acetate
<p>AKN-028 acetate: an oral TK inhibitor for AML research, targets FLT3 with IC50 of 6 nM, inhibits autophosphorylation, and induces apoptosis.</p>Formule :C19H18N6O2Couleur et forme :SolidMasse moléculaire :362.39VEGFR-2-IN-18
<p>VEGFR-2-IN-18 is a potent VEGFR-2 inhibitor with a 60 nM IC50, promoting cell apoptosis and anticancer effects.</p>Formule :C20H13ClN4O2Couleur et forme :SolidMasse moléculaire :376.8CEP-11981
CAS :<p>CEP-11981 is an orally active TIE2/pan-VEGFR inhibitor with broad tyrosine kinase inhibitory activity, antitumour and anti-angiogenic, refractory solid tumours.</p>Formule :C28H27N7ODegré de pureté :99.58%Couleur et forme :SolidMasse moléculaire :477.56EGFR-IN-47
<p>EGFR-IN-47: strong oral EGFRL858R/T790M/C797S blocker, induces cell death; promising for NSCLC research. IC50: 0.01 μM.</p>Formule :C29H35N7Couleur et forme :SolidMasse moléculaire :481.64EGFR-IN-58
<p>EGFR-IN-58 is a potent, selective, ATP-competitive inhibitor of EGFR. EGFR-IN-58 exhibits significant cytotoxicity against melanoma, colon and blood cancers.</p>Formule :C31H30FN7OCouleur et forme :SolidMasse moléculaire :535.61Protein Kinase Inhibitor 12
CAS :<p>Protein Kinase Inhibitor 12 (compound 1-91) is protein kinase inhibitor,PIM-1, CDK-2, GSK-3, and SRC mammalian protein kinases.</p>Formule :C14H14N4OSDegré de pureté :98.06%Couleur et forme :SolidMasse moléculaire :286.35Tofacitinib Prodrug-1
<p>Tofacitinib Prodrug-1: an oral prodrug reducing Tofacitinib's side effects, treats ulcerative colitis in mice effectively with low toxicity.</p>Formule :C36H39ClN10O7Couleur et forme :SolidMasse moléculaire :759.21Anticancer agent 69
<p>Anticancer agent 69 targets PC3 cells (IC50=26 nM), raises ROS, lowers EGFR, and induces apoptosis.</p>Formule :C19H26N8SCouleur et forme :SolidMasse moléculaire :398.53JAK-2/3-IN-3
<p>JAK-2-/3-IN-3 (ST4j) is a potent JAK2/3 inhibitor for leukemia research, with IC50s: JAK2, 13 nM; JAK3, 14.86 nM; induces apoptosis.</p>Formule :C13H10Cl2N4O2Couleur et forme :SolidMasse moléculaire :325.15HER2-IN-12
<p>HER2-IN-12 is an HER2 inhibitor with an IC50 value of 121 nM and can be used to study cancers such as breast cancer.</p>Formule :C17H18BrN5O2SCouleur et forme :SolidMasse moléculaire :436.33VEGFR-IN-3
CAS :<p>VEGFR-IN-3 inhibits cancer cell growth (OVCAR-4, MDA-MB-468) with IC50s: 0.29, 0.35μM. Used in cancer research.</p>Formule :C27H28N2O6Couleur et forme :SolidMasse moléculaire :476.52JAK2/FLT3-IN-1 TFA
<p>JAK2/FLT3-IN-1 (TFA), an oral JAK2/FLT3 inhibitor, shows anticancer properties; IC50: JAK2 (0.7 nM), FLT3 (4 nM), JAK1 (26 nM), JAK3 (39 nM).</p>Formule :C27H35F4N7O3Couleur et forme :SolidMasse moléculaire :581.61DHFR-IN-4
CAS :<p>DHFR-IN-4 is a potent dihydrofolate reductase (DHFR) inhibitor with anti-tumour activity, inhibits EGFR and HER2 and can be used to study pancreatic cancer.</p>Formule :C18H21N5O2SDegré de pureté :99.41%Couleur et forme :SolidMasse moléculaire :371.46EGFR-IN-125
CAS :<p>EGFR-IN-125 (example 37) is a potent EGFR inhibitor with IC50 values of <0.3 nM for EGFR(d746-750/T790M/C797S), 0.52 nM for EGFR(L858R/T790M/C797S), 0.5 nM for EGFR(d746-750/C797S), 0.69 nM for EGFR(L858R/C797S), and 0.92 nM for EGFR (wild type).</p>Formule :C30H26N8OCouleur et forme :SolidMasse moléculaire :514.58JAK3-IN-11
CAS :<p>JAK3-IN-11: potent oral JAK3 inhibitor (IC50=1.7 nM), noncytotoxic, >588-fold selectivity, blocks T-cell growth; useful in autoimmune research.</p>Formule :C23H23N5O2Couleur et forme :SolidMasse moléculaire :401.46EGFR/HER2-IN-7
<p>EGFR/HER2-IN-7: Potent, selective dual inhibitor for MCF-7 cancer; IC50: EGFR 0.18μM, HER2 0.146μM, DHFR 0.907μM.</p>Formule :C19H21N3O2SCouleur et forme :SolidMasse moléculaire :355.45HDAC-IN-35
<p>HDAC-IN-35 (Compound 14) is an effective and selective inhibitor of VEGFR-2 and HDAC, with IC50 values of 13.2 and 0.166 μM for VEGFR-2 and HDAC6, respectively.</p>Formule :C17H13ClF3N3O3Couleur et forme :SolidMasse moléculaire :399.75NDI-034858
CAS :<p>NDI-034858 (TAK-279) is a tyrosine kinase 2 (TYK2) inhibitor (Kd<200 pM) that targets the JH2 structural domain of Tyk2 for the treatment of autoimmune diseases</p>Formule :C23H24N8O3Degré de pureté :>99.99%Couleur et forme :SolidMasse moléculaire :460.49JAK2-IN-7
CAS :<p>JAK2-IN-7 selectively inhibits JAK2 (IC50: 3 nM), shows 14-fold selectivity over JAK1/3, FLT3, induces G0/G1 arrest, apoptosis, and has antitumor effects.</p>Formule :C26H33N7ODegré de pureté :99.54%Couleur et forme :SolidMasse moléculaire :459.59
